Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
PSNL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.14 - $7.20
Previous CloseN/A
Volume738.16K
Average Volume (3M)769.54K
Market Cap
$530.83M
Enterprise Value$433.59M
Total Cash (Recent Filing)$185.69M
Total Debt (Recent Filing)$44.42M
Price to Earnings (P/E)―
Beta1.25
Next Earnings
Aug 06, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding88,325,134
10 Day Avg. Volume920,275
30 Day Avg. Volume769,545
Financial Highlights & Ratios
PEG Ratio-0.93
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-9.85
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue1.28
Enterprise Value/Gross Profit15.19
Enterprise Value/Ebitda-1.48
Forecast
1Y Price Target
$7.14Price Target Upside18.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Personalis News
PremiumCompany Announcements
Personalis Holds Virtual Annual Stockholders Meeting
PremiumCompany Announcements
Personalis Q1 2025 Earnings: Growth and Strategic Advances
Bulls Say, Bears Say
Bulls Say
Clinical DiagnosticsPSNL envisions that its clinical diagnostic testing business, which now consists of its NeXT Personal MRD test and its NeXT Dx therapy selection panel, will consist of 60-70% of its total revenue, up from just 1% now, at a GM of 60%.
Pharma ContractsPSNL has had recent wins with pharma companies, as it announced that it signed two MRD contracts with biopharma companies expected to contribute $5M apiece this year.
Bears Say
Enterprise Sales DeclineRevenue growth improved to 6% in 1Q25 from (15%) growth in 4Q24 as growth in biopharma and VA MVP revenues offset declines in enterprise sales.
Revenue DeclineThe year-over-year revenue decrease was driven by lower Natera and VA MVP volumes.
Ownership Overview
21.82% Insiders
3.23% Mutual Funds
45.08% Other Institutional Investors
19.44% Public Companies and Individual Investors
PSNL FAQ
What was Personalis Inc’s price range in the past 12 months?
Personalis Inc lowest stock price was $1.14 and its highest was $7.20 in the past 12 months.
What is Personalis Inc’s market cap?
Personalis Inc’s market cap is $530.83M.
When is Personalis Inc’s upcoming earnings report date?
Personalis Inc’s upcoming earnings report date is Aug 06, 2025 which is in 51 days.
How were Personalis Inc’s earnings last quarter?
Personalis Inc released its earnings results on May 06, 2025. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.247 by $0.067.
Is Personalis Inc overvalued?
According to Wall Street analysts Personalis Inc’s price is currently Undervalued.
Does Personalis Inc pay dividends?
Personalis Inc does not currently pay dividends.
What is Personalis Inc’s EPS estimate?
Personalis Inc’s EPS estimate is -0.24.
How many shares outstanding does Personalis Inc have?
Personalis Inc has 88,325,134 shares outstanding.
What happened to Personalis Inc’s price movement after its last earnings report?
Personalis Inc reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.247. Following the earnings report the stock price went up 21%.
Which hedge fund is a major shareholder of Personalis Inc?
Currently, no hedge funds are holding shares in PSNL
Personalis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.14 (18.80% Upside)
$7.14 (18.80% Upside)
Blogger Sentiment
Bullish
PSNL Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 523.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
341.91%
12-Months-Change
Fundamentals
Return on Equity
-51.25%
Trailing 12-Months
Asset Growth
39.96%
Trailing 12-Months
Company Description
Personalis Inc
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.
PSNL Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Personalis reported strong revenue growth and significant progress in molecular test delivery and biopharma revenue. The company maintains a healthy cash position and positive guidance for 2025. However, high operating expenses and net loss, alongside the impact of unreimbursed clinical test costs on gross margin, present challenges. Overall, the sentiment leans positive due to the outweighing highlights and the strategic steps towards future reimbursement and revenue growth.Read More>PSNL Stock 12 Month Forecast
Average Price Target
$7.14
▲(18.80%Upside)